# Patent

## Title
Methods of identifying pancreatic cancer cells

## Abstract

Methods that identify cells as pancreatic cancer cells based on assessing the expression of combinations of target molecules expressed preferentially on pancreatic cancer cells are disclosed. Combinations were initially discovered by microarray analysis and selected based upon tumor specificity, relative lack of cross-reactivity with normal tissues, and applicability as targets of multispecific ligands. The claimed methods encompass measuring the expression of three or more specific target molecules in combination and correlating positive expression of the combination with an identification of the cell as a pancreatic cancer cell.

## Background
CROSS REFERENCE TO RELATED APPLICATION
This application claims the benefit of U.S. Provisional Patent Application No. 60/905,120.


STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
This invention was made under grants from the National Institutes of Health (R33CA959944; and R01CA97360).


BACKGROUND OF THE INVENTION
The invention relates generally to methods of identification of cell types on the basis of identification of specific targets, and more specifically to methods of identifying pancreatic cancer cells on the basis of the expression of a particular combination of specific targets.
The targeting of imaging agents or therapeutic agents to molecular targets on the surface of particular cell types holds considerable promise as a research, diagnostic and therapeutic strategy. Cell surface molecules are often favored because their structural diversity and because agents that target cell surface molecules do not need to cross the plasma membrane to reach their targets. Many targeting agents contain one or more moieties capable of specifically binding a single cell surface protein. Such agents include small molecules and monoclonal antibodies. There have been successes using this approach. In one example, a series of RGD-peptide based ligands coupled with a variety of proteins, small molecules, nucleic acids and radiotracers were developed to deliver therapeutics to tumor vasculature (see reference 18). The 18F-Galacto-RGD ligand was tested in humans and showed desirable pharmacokinetics and good visualization of αvβ3-integrin expression under PET scan (see references 19 and 20). Additionally, radiolabeled monoclonal antibodies that target cell surface antigens were approved as a treatment of B-cell non-Hodgkin's lymphoma (see reference 21). However, while such monospecific (also termed monomeric or monovalent) agents have demonstrated some utility in targeting and identifying some tumors, their use is limited the rare instance in which a target is expressed at a high level on tumor relative to normal tissue. Moreover, agents capable of binding only a single cell surface target might not be specific enough to differentiate one cell type from another (in one nonlimiting example, differentiation of a tumor cell from a noncancerous cell). As a result, some monospecific agents used as therapeutics often cause substantial side effects. Similarly, only a small proportion of cell surface targets are overexpressed in solid tumors relative to normal tissues. Therefore, monospecific ligands are useful in only a small proportion of the potential cell surface targets on solid tumors.
A multispecific (also termed multimeric or multivalent) ligand, on the other hand, has multiple binding specificities per ligand. Because a multispecific ligand can bind multiple surface targets on a cell, it has a greater overall affinity and avidity to cells expressing a particular combination of targets with minimal binding to cells that express only some or none of the targets. Such a ligand would also be able to select between very similar cell types, indicating new subpopulations of cells. This would have important implications in the fields of research, diagnostics and therapeutics. See references 11, 22-24. Multispecific ligands, then, have great potential. However, the development of such ligands is has been slowed by the difficulty of identifying combinations of targets that, when concurrently expressed, identify a particular cell type. If multispecific ligands are to become a viable treatment option, methods that identify particular cell types using combinations of targets are necessary.
So as to reduce the complexity and length of the Detailed Specification, and to fully establish the state of the art in certain areas of technology, Applicants herein expressly incorporate by reference all of the following materials identified in each numbered paragraph below. The incorporated materials are not necessarily “prior art” and Applicants expressly reserve the right to swear behind any of the incorporated materials.

    
    
        1. Jemal A et al, Cancer Statistics, CA Cancer J Clin 56, 106-130 (March/April, 2006).
        2. Hale G, Therapeutic antibodies—Delivering the promise?, Adv Drug Deliv Rev, 58 633-639 (May, 2006).
        3. Pegram M D et al, Targeted therapy: wave of the future. J Clin Oncol 23 1776-1781 (2005).
        4. Reichert J M et al, Monoclonal antibody successes in the clinic. Nat Biotechnol 23 1073-1078 (2005)
        5. Richter M and H Zhang, Receptor-targeted cancer therapy. DNA Cell Biol 24 271-282 (2005)
        6. Sawyers C, Targeted cancer therapy, Nature, 432 294-297 (2004).
        7. Vasir J K and Labhasetwar V, Targeted drug delivery in cancer therapy, Technol Cancer Res Treat, 4 363-374 (2005)
        8. Tang P A, M S Tsao and M J Moore, A review of erlotinib and its clinical use, Expert Opin Pharmacother 7 177-193 (February, 2006).
        9. Moore M J, Brief communication: a new combination in the treatment of advanced pancreatic cancer, Semin Oncol 32 5-6 (2005).
        10. Handl H L et al, Hitting multiple targets with multimeric ligands, Expert Opin Ther Targets, 8 565-586 (2004).
        11. Vagner J et al, Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH, Bioorg Med Chem Let 14 211-215 (2004).
        12. Son C G et al, Database of mRNA gene expression profiles of multiple human organs, Genome Res 15 443-450 (2005).
        13. Shyamsundar R et al, A DNA microarray survey of gene expression in normal human tissues, Genome Biol 6 R22.1-R22.7 (2005).
        14. Kallioniemi O P et al, Tissue microarray technology for high-throughput molecular profiling of cancer, Hum Mol Genet 10657-662 (2001).
        15. Nocito A et al, Tissue microarrays (TMAs) for high-throughput molecular pathology research, Int J Cancer, 94 1-5 (2001).
        16. Torhorst J et al, Tissue microarrays for rapid linking of molecular changes to clinical endpoints, Am J Pathol 159 2249-2256 (2001).
        17. Kononen J et al, Tissue microarrays for high throughput molecular profiling of tumor specimens, Nat Med 4 844-847 (1998).
        18. Temming K et al, RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature, Drug Resist Update 8 381-402 (2005).
        19. Haubner R et al, Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F] Galacto-RGD, PLoS Med, 2, 0244-0252 (2005).
        20. Beer A J et al, PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression, J Nucl Med 47, 763-769 (May, 2006).
        21. Goldenberg D M and Sharkey R M. Novel radiolabeled antibody conjugates, Oncogene 26 3734-3744 (May, 2007).
        22. Jhanwar Y S and Divgi C, Current status of therapy of solid tumors, J Nucl Med 46 141S-150S (2005)
        23. Goldenberg D M and Sharkey R M, Advances in cancer therapy with radiolabeled antibodies, Q J Nucl Med Mol Imaging 50 248-264 (December, 2006).
        24. Boturyn D et al, Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis, J Am Chem Soc, 126 5730-5739 (2004).
        25. Handl H L et al, Hitting multiple targets with multimeric ligands, Expert Opin Ther Targets, 8 565-586 (2004).
        26. Laugel B et al, Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition, J Biol Chem 280 1882-1892 (2005).
        27. Garanger E et al, Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands, Org Biomol Chem, 4 1958-1965 (April, 2006).
        28. Mammen M et al, Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors, Angewandte Chemie 37 2754-2796 (1998).
        29. Boyd R S et al, Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B, Leukemia 17 1605-1612 (2003).
        30. Zhao Y et al, Proteomic analysis of integral plasma membrane proteins. Anal Chem, 76 1817-1823 (2004).
        31. Loyet K M et al, Proteomic profiling of surface proteins on Th1 and Th2 cells. J Proteome Res, 4 400-409 (2005).
        32. Tangrea M A et al, Novel proteomic approaches for tissue analysis, Expert Rev Proteomics 1 185-92 (2004).
        33. Dougherty E R et al, Inference from clustering with application to gene-expression microarrays, J Comput Biol, 9 105-126 (2002).
        34. Andersen C L et al, Improved procedure for fluorescence in situ hybridization on tissue microarrays, Cytometry 45 83-86 (2001).
        35. Mousses S et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays, Cancer Res 62 1256-1260 (2002).
        36. Watanabe A et al, Tissue microarrays: applications in genomic research, Expert Rev Mol Diagn, 5 171-181 (2005).
        37. Morse D L et al, Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction, Anal Biochem 342 69-77 (2005).
        38. Lynch R M et al, Modulation of hexokinase association with mitochondria analyzed with quantitative three-dimensional confocal microscopy, J Cell Biol 112 385-395 (1991).
        39. Rose A, The sensitivity performance of the human eye on an absolute scale, J Opt Soc Am 38 196-208 (1948).
        40. Barrett H H and Swindell W, Noise in Images. In: Barrett H H, Swindell W, eds Radiological Imaging: Academic Press 494-560 (1981).
    
    


Applicants believe that the material incorporated above is “non-essential” in accordance with 37 CFR 1.57, because it is referred to for purposes of indicating the background of the invention or illustrating the state of the art. However, if the Examiner believes that any of the above-incorporated material constitutes “essential material” within the meaning of 37 CFR 1.57(c)(1)-(3), applicants will amend the specification to expressly recite the essential material that is incorporated by reference as allowed by the applicable rules.
BRIEF SUMMARY OF THE INVENTION
The present invention provides among other things a method of identifying a cell as a pancreatic cancer cell based on assessing the expression of combinations of targets.
It is an object of the invention to identify a cell as a pancreatic cancer cell by analyzing the expression of a particular combination of at least three targets.
It is an object of the invention to identify a cell as a pancreatic cancer cell by assessing the expression of a particular combination of at least four targets.
It is an object of the invention to identify a cell as a pancreatic cancer cell through microarray analysis of the expression a particular combination of targets.
It is an object of the invention to identify a cell as a pancreatic cancer cell using labeled antibodies to analyze the expression of a particular combination of targets
It is an object of the invention to identify a cell as a pancreatic cancer cell through immunohistochemistry analysis of the expression of a particular combination of targets.
It is an object of the invention to identify a cell as a pancreatic cancer cell through immunohistochemistry analysis of the expression of a particular combination of targets expressed on a tissue microarray.
It is an object of the invention to identify a cell as a pancreatic cancer cell using immunocytochemistry analysis of the expression of a particular combination of targets.
It is an object of the invention to identify a cell as a pancreatic cancer cell using a flow cytometer to analyze the expression of a particular combination of targets.
It is an object of the invention to identify a cell as a pancreatic cancer cell by reverse transcriptase polymerase chain reaction (RTPCR).
It is an object of the invention to identify a cell as a pancreatic cancer cell by quantitative real time reverse transcriptase polymerase chain reaction (qRT-RTPCR).
It is an object of the invention to identify a cell as a pancreatic cancer cell using a multispecific targeting agent to analyze the expression of a particular combination of targets.
It is an object of the invention to detect a pancreatic cancer cell using a labeled multispecific targeting agent capable of specifically binding a combination of a set of cell surface proteins that, when expressed in combination, identify a cell as a pancreatic cancer cell.
It is an object of the invention to identify a cell as a pancreatic cancer cell using a multispecific targeting agent that is conjugated with an agent toxic to the cell and is capable of specifically binding a combination of cell surface proteins that identify a cell as a pancreatic cancer cell.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, IL1RAP, and SLC01B3 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, IL1RAP, and PTPRR isoform 1 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, IL1RAP, and PTPRR isoform 2 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, IL1RAP, and SLCA2A13 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, SLC01B3, and FCGR1A in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, SLC01B3, and CLEC4A isoform 1 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, SLC01B3, and CLEC4A isoform 2 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, SLC01B3, and CLEC4A isoform 3 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, SLC01B3, and CLEC4A isoform 4 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, TM4SF4, and SLC21A3 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB10, TM4SF4, and FCGR1A in combination. The above and other objects may be achieved using methods involving assessing the expression of TM4S4, IL1RAP, FCGR1A, and ASGR1 in combination.
The above and other objects may be achieved using methods involving assessing the expression of TM4S4, IL1RAP, PCDHB10, and PCDHB9 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 1, SLC01B3, ASGR1, and PTPRC isoform 1 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 1, SLC01B3, ASGR1, and PTPRC isoform 2 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 1, SLC01B3, ASGR1, and PTPRC isoform 3 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 1, SLC01B3, ASGR1, and PTPRC isoform 4 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 2, SLC01B3, ASGR1, and PTPRC isoform 1 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 2, SLC01B3, ASGR1, and PTPRC isoform 2 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 2, SLC01B3, ASGR1, and PTPRC isoform 3 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 2, SLC01B3, ASGR1, and PTPRC isoform 4 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 1, SLC01B3, ASGR1, and MS4A4A in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 2, SLC01B3, ASGR1, and MS4A4A in combination.
The above and other objects may be achieved using methods involving assessing the expression of TM4S4, TNFSF4, MGC34293, and TGFBR1 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PCDHB8, HLA-DQA1, PCDHB10, and SLC01B3 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 1, CEACAM6, MS4A4A, and SLC01B3 in combination.
The above and other objects may be achieved using methods involving assessing the expression of PTPRR isoform 2, CEACAM6, MS4A4A, and SLC01B3 in combination.
Aspects and applications of the invention presented here are described below in the drawings and detailed description of the invention. Unless specifically noted, it is intended that the words and phrases in the specification and the claims be given their plain, ordinary, and accustomed meaning to those of ordinary skill in the applicable arts. The inventors are fully aware that they can be their own lexicographers if desired. The inventors expressly elect, as their own lexicographers, to use only the plain and ordinary meaning of terms in the specification and claims unless they clearly state otherwise and then further, expressly set forth the “special” definition of that term and explain how it differs from the plain and ordinary meaning. Absent such clear statements of intent to apply a “special” definition, it is the inventors' intent and desire that the simple, plain and ordinary meaning to the terms be applied to the interpretation of the specification and claims.
The inventors are also aware of the normal precepts of English grammar. Thus, if a noun, term, or phrase is intended to be further characterized, specified, or narrowed in some way, then such noun, term, or phrase will expressly include additional adjectives, descriptive terms, or other modifiers in accordance with the normal precepts of English grammar. Absent the use of such adjectives, descriptive terms, or modifiers, it is the intent that such nouns, terms, or phrases be given their plain, and ordinary English meaning to those skilled in the applicable arts as set forth above.
Further, the inventors are fully informed of the standards and application of the special provisions of 35 U.S.C. §112, ¶6. Thus, the use of the words “function,” “means” or “step” in the Detailed Description or Description of the Drawings or claims is not intended to somehow indicate a desire to invoke the special provisions of 35 U.S.C. §112, ¶6, to define the invention. To the contrary, if the provisions of 35 U.S.C. §112, ¶6 are sought to be invoked to define the inventions, the claims will specifically and expressly state the exact phrases “means for” or “step for, and will also recite the word “function” (i.e., will state “means for performing the function of [insert function]”), without also reciting in such phrases any structure, material or act in support of the function. Thus, even when the claims recite a “means for performing the function of . . . ” or “step for performing the function of . . . ,” if the claims also recite any structure, material or acts in support of that means or step, or that perform the recited function, then it is the clear intention of the inventors not to invoke the provisions of 35 U.S.C. §112, ¶6. Moreover, even if the provisions of 35 U.S.C. §112, ¶6 are invoked to define the claimed inventions, it is intended that the inventions not be limited only to the specific structure, material or acts that are described in the preferred embodiments, but in addition, include any and all structures, materials or acts that perform the claimed function as described in alternative embodiments or forms of the invention, or that are well known present or later-developed, equivalent structures, material or acts for performing the claimed function.



BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
A more complete understanding of the present invention may be derived by referring to the detailed description when considered in connection with the following illustrative figures. In the figures, like reference numbers refer to like elements or acts throughout the figures.
FIG. 1 depicts multidimensional scaling plots of the pancreatic tumor tissues (black dots) and normal tissues (gray dots) based on microarray expression data.
FIG. 2 depicts microarray intensity distribution plots of pancreatic tumor samples (dashed line) and normal tissue samples (solid line). Vertical lines show cutoff values demarcate a target as either “positively expressed” in a given tumor sample (dashed line with a circle) or “not expressed” in a given normal sample (dashed line with a cross).
FIG. 3 depicts a dendrogram of pancreatic tumor tissue groupings with normal tissues based on expression of cell-surface targets. NMel: normal melanocytes; Nhea: Normal heart; NCol: Normal colon; NBre: Normal breast; NOva: Normal ovary; NOst: Normal osteoblasts; NSal: Normal salivary gland; NSke: Normal skeletal muscle; NAdi: Normal adipose tissue; NAdr: Normal Adrenal gland; NSto: Normal stomach; NCar: Normal cartilage tissue; NPan: Normal pancreas; TPan: Pancreatic tumor samples.
FIG. 4 depicts validation of target combinations by tissue microarray (TMA) based immunohistochemistry. The pancreatic tumor TMA (left) was constructed by Applicants and the normal tissue microarray (right) was obtained from NCI's cooperative tissue network.



Elements and acts in the figures are illustrated for simplicity and have not necessarily been rendered according to any particular sequence or embodiment.
DETAILED DESCRIPTION OF THE INVENTION
In the following description, and for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the various aspects of the invention. It will be understood, however, by those skilled in the relevant arts, that the present invention may be practiced without these specific details. In other instances, known structures and devices are shown or discussed more generally in order to avoid obscuring the invention. In many cases, a description of the operation is sufficient to enable one to implement the various forms of the invention, particularly when the operation is to be implemented in software. It should be noted that there are many different and alternative configurations, devices and technologies to which the disclosed inventions may be applied. The full scope of the inventions is not limited to the examples that are described below.
Herein, Applicants describe methods of using combinations of targets expressed by pancreatic cancer cells in order to identify a cell as a pancreatic cancer cell. Targets include any molecular structure produced by a cell and expressed inside the cell, on the cell surface, or secreted by the cell. Targets include proteins, lipids, carbohydrates, nucleic acids, and combinations thereof including subcellular structures, glycoproteins, and viruses. Preferably, the targets include proteins or glycoproteins associated with the cell membrane. A target associated with the cell membrane may achieve said association with the cell membrane by some hydrophobic or other membrane-directing domain such as a membrane-spanning domain. Alternatively, a target may be associated with the cell membrane by as part of a complex of two or more proteins, one of which is directly associated with the cell membrane.
Expression encompasses all processes through which specific molecules may be derived from a nucleic acid template. Expression thus includes RNA transcription, mRNA splicing, protein translation, protein folding, post-translational modification, membrane transport, associations with other molecules, addition of carbohydrate moeties to proteins, phosphorylation, protein complex formation and any other process through which specific biological material may be made from a nucleic acid template. Expression also encompasses all processes through which the production of material derived from a nucleic acid template may be actively or passively suppressed. Such processes include all aspects of transcriptional and translational regulation. Examples include heterochromatic silencing, transcription factor inhibition, any form of RNAi silencing, alternative splicing, protease digestion, post-translational modification, and alternative protein folding. Expression is an integral process of a target in that without expression of the target, there would be no target.
Expression may be assessed by any of a number of methods used to detect material derived from a nucleic acid template used currently in the art and yet to be developed. Examples of such methods include any nucleic acid detection method including the following nonlimiting examples, microarray analysis, RNA in situ hybridization, RNAse protection assay, Northern blot, RTPCR, and QRTPCR. Other examples include any process of detecting expression that uses an antibody including the following nonlimiting examples, flow cytometry, immunohistochemistry, ELISA, Western blot, and immunoaffinity chromatograpy. Antibodies may be monoclonal, polyclonal, or any antibody fragment including an Fab, F(ab)2, Fv, scFv, phage display antibody, peptibody, multispecific ligand, or any other reagent with specific binding to a target. Such methods also include direct methods used to assess protein expression including the following nonlimiting examples: HPLC, mass spectrometry, protein microarray analysis, PAGE analysis, isoelectric focusing, 2-D gel electrophoresis, and enzymatic assays. Samples from which expression may be detected include single cells, whole organs or any fraction of a whole organ, whether in vitro, ex vivo, in vivo, or post-mortem. Preferably the sample includes cells derived from human pancreas.
Methods to detect targets may include the use of a ligand with specificity for the target. Ligands may be monospecific (also termed monomeric or monovalent) as well as multispecific (also termed multimeric or multivalent). Monospecific ligands have at least one target binding site, but only one specificity per ligand while multispecific ligands have at least two target binding sites per ligand. While all binding sites on monospecific ligands are equivalent, multispecific ligands include at least two different types of binding site per ligand. Such binding sites on a multispecific ligand may have specificity for different targets or for different epitopes on the same target. Ligands (whether monospecific or multispecific) include antibodies, antibody complexes, conjugates, natural ligands, small molecules, nanoparticles, any combination of molecules that includes one or more of the above, or any other molecular entity capable of specific binding to a target existing now or developed in the future. Monospecific and multispecific ligands may be associated with a label such as a radioactive isotope or chelate thereof, dye (fluorescent or nonfluorescent,) stain, enzyme, nonradioactive metal, or any other substance capable of aiding a machine or a human eye from differentiating a cell expressing a target from a cell not expressing a target whether in existence now or developed in the future. Additionally, expression may be assessed by monospecific or multispecific ligands associated with substances capable of killing the cell. Such substances include protein or small molecule toxins, cytokines, pro-apoptotic substances, pore forming substances, radioactive isotopes, or any other substance toxic to a cell that may be delivered to a cell by a ligand.
Positive expression includes any difference between a cell expressing a specific target and a cell that does not express a specific target. The exact nature of positive expression varies by the method, but is well known to those skilled in the art of practicing a particular method. Positive expression may be assessed by a detector, an instrument containing a detector, or by aided or unaided human eye. Examples include but are not limited to specific staining of cells expressing a target in an IHC slide, binding of RNA from a sample to a microarray and detection by said microarray, a high rate of dye incorporation in real-time RTPCR, detection of fluorescence on a cell expressing a target by a flow cytometer, the presence of radiolabeled bands on film in a Northern blot, detection of labeled blocked RNA by RNAse protection assay, cell death measured by apoptotic markers, cell death measured by shrinkage of a tumor, or any other signal for the expression of a target in existence now or yet to be developed.
A specific target may be identified by the sequence of a nucleic acid from which it can be derived (see Table 8). Examples of such nucleic acids include mRNA, cDNA, or genomic sequences. Alternatively, a specific target may be identified by a protein sequence. However, the specific target is not limited to the products of the exact nucleic acid sequence or protein sequence by which it may be identified. Rather, a specific target encompasses all sequences that yield positive expression when the expression of the specific target is assessed. Examples of sequences encompassed by a specific target identified by a nucleic acid molecule include point mutations, silent mutations, deletions, frameshift mutations, translocations, alternative splicing derivatives, differentially methylated sequences, differentially modified protein sequences, and any other variation that results in a product that may be identified as the specific target. The following nonlimiting example is included for the purposes of illustrating the concept of what is encompassed by a target: if expression of a specific target in a sample is assessed by immunohistochemistry, and if the sample expresses a sequence different from the sequence used to identify the specific target (e.g. a variation of one or more nucleic acid molecules,) but positive expression is still determined, then the target encompasses the sequence expressed by the sample.
In one aspect of the invention, target expression may be assessed by microarray. The following protocol is included solely to illustrate one example of this aspect of the invention. This aspect also encompasses any variation the following protocol including any method that assesses the expression of a target through the binding of a complimentary nucleic acid probe. In addition, the following protocol describes the methodology used in identifying combinations of targets that identify cells as prostate cancer cells. Total RNA is isolated from tissues using the NucleoSpin RNA II isolation kit (BD Biosciences, Palo Alto, Calif.) following manufacturer's instructions hereby incorporated by reference. The microarray analysis including target labeling and chip hybridization and processing are carried out by following the protocols recommended by the manufacturer, (Agilent Technologies, Palo Alto, Calif.), hereby incorporated by reference. Briefly, 1 μg of total RNA is used to generate CY5 cRNA targets using the Agilent low input RNA fluorescent linear amplification kit, using manufacturer's protocol, hereby incorporated by reference. A total RNA sample isolated from normal pancreas is labeled with CY3 to serve as a reference. The concentration and integrity of fluorescent cRNA as well as the incorporation efficiency of cyanine dyes are analyzed using the Agilent 2100 Bioanalyzer RNA microfluidics chip following manufacturer's protocols, hereby incorporated by reference. Equal amounts of labeled cRNA targets from the tissue sample and the universal reference are hybridized onto Agilent Human 1A and Agilent Human 1A (V2) oligonucleotide arrays. The hybridization signals are acquired and normalized using Agilent's Feature Extraction Image Analysis software (v.7.1).
To obtain targets useful in detecting cells as pancreatic cancer cells, DNA microarray expression data was assessed in three pancreatic cell lines, all of which were obtained from the American Type Tissue Collection (ATCC), were generated using the same procedure using total RNA isolated from cells grown to  ̃80% confluent. The arrays include 18,778 and 22,073 individual 160-mer probes, respectively. Microarray data was obtained from the 105 normal tissue/cell samples representing 28 different organ sites/cell types. In addition, microarray data was obtained from 28 pancreatic adenocarcinoma tissue samples. The feature intensities derived from each sample were first normalized by the median intensity value of the array in order to cross compare different samples run on different chips. Multidimensional scaling (MDS) analysis was used to test the internal consistency of the data set by checking the clustering of the individual samples. As shown in FIG. 1, despite the fact that the tissues were obtained from different sources and represent diverse ethnic, age and sex groups, normal tissue samples belonging to the same organ type tend to cluster together. In contrast to this observation, the pancreatic tumor samples were not always clustered, indicating more heterogeneous expression patterns in the pancreatic tumors.
Applicants focused upon targets expressing putative cell surface molecules included in the Agilent Human 1A and 1A V2 oligonucleotide array, with cell surface or transmembrane regions. A total of 2133 targets met their criteria. Applicants then manually examined the cellular localization of each target by browsing through information in databases (Genecard, Harvester, Entrez, Protein Database, UniProt and PubMed) and literature (PubMed). Targets encoding proteins with putative cell-surface or transmembrane regions were also included. The final list consists of 2,133 targets, including GPCRs, integral membrane proteins and other cell surface proteins. Each category was followed through the hierarchy to the lowest possible level in order to select lists containing targets with cell-surface epitopes, while excluding lists that were sure to not include cell-surface proteins. A list was compiled from all of the selected lists containing 6,389 targets. Since Applicants intended to use this list to assess expression using the Agilent Human 1A (V2) oligonucleotide array chips, Applicants removed targets from our cell-surface list that were not represented on the Agilent array. The resulting new list contained 4,407 targets. Each target on the master list was then checked using information from existing databases (Genecard, Harvester, Entrez, Protein Database, UniProt and PubMed) to determine if it encodes a cell surface protein, if it is predicted to encode one by similarity or homology, if it is a non cell-surface target, or if the sub-cellular localization is not determinable. Non cell-surface targets were removed from the list. The resulting list was thus enriched with targets expected to encode proteins that have epitopes exposed on the cell surface. Our final list contains a total of 2177 targets covered by the Agilent Human 1A V2 and 1928 targets covered by the 1A (V1).
Hierarchical clustering (agglomerative procedure) was used to form clusters using the median normalized microarray expression data of the cell surface targets of the tissue samples. The object of this clustering analysis is to compute a dendrogram that assembles all tissue samples into a single tree based on their similarities in cell surface target expression (see FIG. 3). The clustering algorithm used is based on the average-linkage method as described in reference 17. Since our tissue samples had 29 distinct types (28 different normal tissue/cell types plus the pancreatic tumor tissue group), the repetitive clustering process was stopped when it formed 29 groups.
Referring now to FIG. 2, the frequency histogram of mRNA abundance follows a pseudo-power law. Thus, an important component of the effort includes assessing RNA expression from non-expression when using microarray analysis. Because the level of mRNA expression is not always linearly related to the level of protein translation and subsequent localization to the cell surface, Applicants determined the relationship between assessing the expression of targets through microarray and assessing the expression of targets through methods that measure protein at the cell surface. The normal and tumor threshold values (indicated in the vertical lines in FIG. 2) were adjusted in order to provide the target combinations with the maximum stringency of the coverage analyses. DNA array intensities below the value of normalized normal tissue threshold values are considered not to have positive expression. Intensities above tumor tissue threshold values displayed positive expression. Setting a normal tissue based threshold value of 0.35, provided no combinations while using any higher tumor cutoff setting. Setting a tumor area based threshold value of 0.75, provided no combinations while using any lower normal cutoff setting. Area based cutoffs that provided target combinations ranged from 0.35 to 0.55 in normal tissues, and 0.55 to 0.75 in tumor tissues. Combinations that provided the highest coverage amongst tumor tissues with the most stringent cutoff values were selected.
To further demarcate positive expression from non-expression, Applicants quantified the expression of common CD (Cluster of Differentiation) targets using Europium-labeled antibodies binding to three different cell lines (Mia PaCa-2, BxPC-3 and Capan-2) with varying RNA expression as determined by microarray of the CD targets. Results are summarized in Table 7. Binding was quantified on whole cells using time resolved fluorescence and indicated that median normalized intensities of 0.55 as measured in microarray analysis corresponded to the minimum detectable protein level above the background signal. However, CD antibody binding data also showed that higher microarray intensity does not necessarily indicate a high binding signal. Applicants used a median microarray intensity ratio of 0.45 non-expression cutoff in normal tissue samples. Applicants used microarray intensity levels from 0.55 to 0.85 as a positive expression cutoff in pancreatic tumor tissue samples. Microarray data were parsed with these varying levels of upper cutoff to generate binarized data with a value of 1 to signify positive expression and 0 to signify non-expression.
Microarray data were generated using eleven pancreatic adenocarcinoma cell lines. From these data, five lines (AsPC-1, Capan-1, HPAFII, PSN-1 and SU86.86) were selected that may express all three targets in at least one of the validated three-target combinations. Expression of the four validated targets (IL1RAP, PCDHB10, PTPRR and SLC1A13) was determined quantitatively at the level of mRNA by qRT-PCR, and qualitatively at the level of protein by immunocytochemistry (ICC) (results summarized in Table 7). Cell lines were identified that express all three targets in both validated combinations, e.g. AsPC-1 and Capan-1 cells express targets in both combinations at relatively high levels. When expression of the IL1RAP-PCDHB10-PTPRR combination was assessed, Capan-1 cells expressed mRNA ranging from 0.006-0.05 the level of β-actin (ACTB) mRNA and demonstrated relatively high staining of all three targets by ICC.
When assessing the expression of cells with a multispecific targeting agent, the binding avidity to a cell is determined by the binding affinities of the individual ligands that make up the agent to the respective target receptors as well as by the presence and concentration of each target receptor on the cell surface. The cellular specificity of a multispecific targeting agent is largely determined by differences in the expression of each target protein between normal and tumor tissues. In the following nonlimiting example: a multispecific ligand that binds to 3 different target proteins in a tumor and only 1 protein in a normal tissue (difference of 2 in the number of proteins it binds) will have a higher specificity than a ligand that binds to 3 proteins in a tumor and 2 proteins in a normal tissue (difference of 1 in the number of proteins).
Based on the results of empirical studies, Rose and others have determined that detection of an image detail by the human eye requires a signal intensity to background noise ratio (SNR) of at least 2 to 3 (see references 39 and 40). Thus, in the case of imaging, a 3-fold signal enhancement in a target tissue relative to background enhancement is generally required. Further, it is estimated that in the case of targeted therapies, a 100-fold increase in binding to target tissue relative to normal tissues is required (see reference 25). Vagner and others have reported that ligands exhibiting heterobivalent binding interactions demonstrate an  ̃50-fold increase in binding relative to monovalent interactions (see reference 11). An  ̃100-fold increase in homotrivalent binding interactions relative to monovalent interactions was also demonstrated (see references 11 and 28).
From these observations of cooperative affinity, Applicants selected combinations of targets with a difference of 2 in the number of targets in tumor tissue relative to normal tissue. That is, if a combination contains N targets and the tumor expresses all N targets, no more than N-2 targets may be expressed in any given normal tissue by microarray. In the case of two-target combinations, neither target may be expressed in normal tissue. To identify target combinations that meet this rule, the expression of the cell surface targets was binarized to non-expression or positive expression in each tissue sample using area-based cutoff values with the highest possible stringency
To rank the target combinations by their coverage of tumor samples, a coverage flag ‘1’ was assigned to a tumor sample if positive expression of a given target combination was at least N-2 greater than in all normal samples. Otherwise, the tumor sample was assigned ‘0’. This process is repeated with each individual tumor sample and the combination was ordered based on the coverage (‘average coverage flag’) obtained from all the tumor samples. Thus, the highest ranked combinations covered the most tumors with low to no avidity to most, if not all, normal tissues. Because higher dimensional combinations might be computed, it is possible that the same tumor samples could be covered by lower dimensional combinations. In order to only select combinations that cover more tumor samples than any lower dimension combinations Applicants introduced the Coverage Measurement (Ψ) to quantify each combination. If Ψq is the Coverage Measurement of the qth dimension, then a combination with q+1 dimensions is said to have an improvement in coverage over a combination with q dimensions only if: Ψq+1>Ψq. Only combinations with a higher Coverage Measurement than all combinations with lower dimensions (Ψq+1>v{Ψ1, Ψ2, . . . , Ψq}) were selected as valid target combinations.
To identify single targets, Applicants assessed the expression of each of the targets in the final list (above) in both pancreatic tumors and normal pancreas. Using a median normalized ratio of 0.45 as the non-expression cutoff in normal pancreas and 0.85 as the positive expression cutoff in pancreatic tumor tissues, Applicants produced a list of targets non-expressed in normal pancreas but expressed in at least 20% of the pancreatic cancer patient samples. Targets with positive expression in normal liver, heart, kidney, lung and pancreas, or in two or more other normal tissue types were eliminated from further consideration.
The analysis resulted in a set of three-target and four-target combinations that each cover at least 3 out of 28 (11%) of pancreatic tumor samples assessed. The three-target combinations are listed in Table 2 and the four-target combinations are listed in Table 3. Combinations containing more than four targets may be assembled using the three- and four-target combinations, and other aspects of the invention encompass these combinations as well. FIG. 3 is a dendrogram that reveals a clustering of pancreatic tumor tissues into four groupings by expression of cell-surface targets, with 96% of the tumor tissues being divided between three major groupings (I, II and IV). Group II contains two very close clusters (the Nsto2/TPan18 cluster and the TPan16/TPan19-TPan25/TPan27-TPan28 cluster). Group IV tumors clustered with the normal pancreas tissue, indicating that these tumors may be difficult to distinguish from normal pancreatic tissue by cell-surface expression, or that the tumor biopsy samples in group IV contain a high percentage of normal tissue. Groups I and II each contain 39% of the tumor samples. The three- and four-target combinations that were identified as having the broadest tumor coverage, predominantly covers tumors in group II, with three of the seven 3-target combinations also covering the single tumor in group III, one of the seven 4-target combinations covered the single tumor in group III and three of the seven covered one tumor in group I. Together, the combinations identified cover 100% of the group II tumors.
In one aspect of the invention, expression of a target may be assessed within the context of a tissue. The following protocol is included solely to illustrate one example of this aspect of the invention. This aspect of the invention encompasses all variations on the protocol and any other protocol that results in a set of one or more tissues that facilitates assessing the expression of a target. Such tissues include whole, excised, post mortem, frozen or paraffin embedded sections, or tissues presented in the context of a tissue microarray (TMA.) To construct a tissue microarray, morphologically representative areas of tumors were selected from formalin fixed tissue samples embedded in paraffin blocks. Two 1.5 mm diameter cores per case were re-embedded in a tissue microarray using a tissue arrayer according to Kononen's method (see reference Number 17). An average of 200 sections can be cut from one tissue microarray block. Using this procedure, Applicants examined two pancreatic tissue microarrays (shown in FIG. 4). To construct a TMA, formalin-fixed paraffin embedded tissues were examined with H&E staining of whole sections to identify pathological distinct areas of interest. With each tissue block, areas representative of tumor, borderline and normal were selected to punch 1.0 mm-diameter discs (two discs per tumor, one disc per border line normal and one disc per normal) used in TMA construction. The discs were re-embedded into a new paraffin block using a tissue arrayer (See references 17 and 34-36). A total of 52 pancreatic ductal adenocarcinoma cases, 38 of which also included a disc from adjacent normal region, 2 cases of pancreatitis and 2 cases of normal pancreas samples were included in the array. After the completion of the block, 5-μm sections were cut with a microtome. The TMA slides were dipped in paraffin in order to achieve uniform epitope preservation. The entire TMA block was sectioned with H & E staining every 50 sections to assess retention of desired tissue targets. TMA slides containing normal tissues were obtained from the Corporative Human Tissue Network of the National Cancer Institute, National Institutes of Health, Bethesda Md. (Version CHTN2002N1). This normal tissue TMA series contains 66 human tissue types in 0.6 mm spot sizes (chtn.nci.nih.gov).
In one aspect of the invention, target expression may be assessed by immunohistochemistry. The following protocol is included solely to illustrate one example of this aspect of the invention. This aspect of the invention encompasses all variations on the protocol and any other protocols that may assess the expression of a target using an agent capable of specifically binding the target in the context of a section of tissue. Antibodies capable of specifically binding to one of the targets are titrated against regular tissue sections and ‘tester’ TMA slides that contain a variety of tumor and normal counterpart tissues in order to optimize the binding conditions. TMA slides are subjected to antigen retrieval by heating at 100° C. in citrate buffer (0.1 M, pH 6.0) for 5-30 min, depending on the antibody used. The slides are incubated with the primary antibodies at the optimized dilutions for 30 minutes at room temperature. Biotinylated secondary antibodies are applied to the tissues, as is streptavidin-peroxidase complex. Binding is resolved with diaminobenzidine (DAB). Slides are evaluated using light microscopy and scored (0=negative, to 3+=intensely positive). Examples of primary antibodies, their sources, and the dilutions used in TMA staining include: rabbit anti-PTPRR (Orbigen Inc, San Diego, Calif.), 1:100; rabbit anti-SLC2A13 (Unites States Biological, Swampscott, Mass.), 1:300; mouse anti-PCDHB10 (Abnova corporation, Teipei, ROC), 1:75; and rabbit anti-IL1RAP (Abcam Inc., Cambridge, Mass.), 1:150. These antibodies cover of two of the three-target combinations listed in Table 2 in their entirety and contain at least one target in the remaining three target combinations listed in Table 2. In addition, these antibodies cover two targets in one of the four-target combinations listed in Table 3 and at least one target in five of the four-target combinations listed in Table 3.
Scoring results are summarized in Table 4. In brief, defining positive expression as a score of 2+ or above, all four targets displayed positive expression in most tumor tissues and non-expression in the normal, non-diseased tissues. The target PTPRR was positively expressed in 75% of the tumor cases assessed, the target PCDHB 10 was positively expressed in 37% of the tumor cases assessed, the target IL1RAP was positively expressed in 48% of the tumor cases assessed, and the target SLC2A13 was positively expressed in 47% of the tumor cases assessed. Non-expression was seen in all normal pancreas assessed.
In addition, expression of two target combinations on normal non-pancreatic tissue was assessed. The results obtained from the combination of PTPRR, IL1RAP and PCDHB10 are summarized in Table 5, while the results obtained from the combination of IL1RAP, PCDHB10, and SLC2A13 are summarized in Table 6. Positive expression (score of greater than 2+) of PTPRR was seen in the gastric mucosa, fallopian tube, adrenal gland and kidney. Positive expression of IL1RAP was seen in small intestine, fallopian tube, and bladder epithelium, positive expression of PCDHB10 was seen in the adrenal gland and kidney, and positive expression of ELC2A13 was not seen in any of the tissues assessed in Table 6. So the PTPRR, IL1RAP, and PCDHB10 combination displays positive expression of two of the targets in fallopian tube, adrenal gland, and kidney. The IL1RAP, PCDHB10, and SLC2A13 combination displays positive expression in fallopian tube only.
In another aspect of the invention, expression may be assessed by quantitative real-time reverse-transcriptase PCR (qRT-RTPCR.) The following protocol is included solely to illustrate one example of this aspect of the invention. This aspect of the invention encompasses all variations of the following protocol including any protocol through which target RNA expression may be assessed through a PCR or other nucleic acid amplification. Additionally, this aspect of the invention encompasses assessing target RNA in any sample including whole tissue, biopsy samples, necropsy samples, punches, cells removed by laser-capture microdissection, or any other samples that may contain one or more mRNA molecule in a condition that allows amplification by any method. The protocol is based upon the qRT-RTPCR protocol in reference 22, but with the following alterations. Primer sets are designed to amplify fragments derived from ACTB (β-actin), IL1RAP, PCDHB10, PTPRR, and SLC2A13 mRNA, and PCR conditions are determined (summarized in Table 1). Real-time RT-PCR is conducted using a Smart Cycler® (Cephid, Sunnyvale, Calif.)—the operations manual of which is herein incorporated by reference—and the QuantiTect SYBR Green RT-PCR Kit (Qiagen, Valencia, Calif.)—manufacturers protocol hereby incorporated by reference. Reverse transcriptase (RT) conversion of RNA into cDNA may be performed during a 20 min (HotStarTaq) incubation at 50° C., followed by a 15 min incubation at 95° C. followed by 35 of the following cycles (15 seconds at 94° C., 30 seconds at a primer-set specific annealing temperature, and 20 seconds at 72° C.).
Melt curves ranging from 60 to 90° C. yielded a single melt-peak in all template reactions and a minimal melt peaks in the no-template control reaction. Raw mRNA expression values were determined as being 2−CT, where CT is the second derivative of the fluorescence curve. Target expression was normalized to ACTB expression. Target expression was assessed in the AsPC-1, Capan-1, HPAFII, PSN-1 and SU86.86 cell lines, summarized in Table 7 using three extracts per cell line (to determine mean and standard error.) Reproducibility of measurements by this method is high (Cronbach's alpha of 0.93 (see reference 37)) so only one run per primer set per extract was performed. Results are reported in Table 7 as the mean and error is reported as standard error of the mean (sem).
In another aspect of the invention, expression may be assessed by immunocytochemistry (ICC.) The following protocol is included solely to illustrate one example of this aspect of the invention. This aspect includes all variations on the protocol as well as any protocol that may be used to assess expression of a target using fluorescently labeled ligands capable of specifically binding to one or more targets, including assessment of expression in a flow cytometer. The protocol is based upon that reported by Lynch, et al (see reference 38) and uses the same primary antibodies capable of specifically binding IL1RAP, PTPRR, and SLC2A13 used in the immunohistochemistry example above. The secondary antibody used to stain IL1RAP, PTPRR and SLC2A13 antibodies in this example is Molecular Probes® AlexaFluor488 Goat Anti Rabbit (Invitrogen, San Diego, Calif.), and the secondary antibody used to stain PCDHB10 antibody is Molecular Probes® AlexaFluor488 Goat Anti-mouse (Invitrogen, San Diego, Calif.). Primary antibodies are diluted 1:50 and secondary antibodies are diluted 1:200. Cells are grown to 80% confluence on glass coverslips in 6-well plates. ICC was performed in duplicate on each cell-line and primary antibody combination. Control experiments are performed on each cell line by not including eliminating the primary antibody incubation. Following incubation, coverslips are mounted on slides using Vectashield fluorescence mounting medium (Vector Laboratories, Burlingame, Calif.) and slides stored in the dark at −20° C. until scoring. Scoring is performed using an A.G. HeinzeTM Precision MicroOptics TS100 inverted microscope with fluorescence and mounted digital camera (A.G. Heinze, Inc., Lake Forest, Calif.). Positive expression was assessed as ++ or above and non-expression as + or below. Results are summarized in Table 7.
In one aspect of the invention, expression is assessed using a multispecific (also known in the art as multimeric) targeting agent. Multispecific targeting agents may be comprised of more than one binding domain tethered together via a linker or scaffold. Other examples of multispecific targeting agents include bispecific antibodies, complexes that include binding sites capable of binding to multiple targets or multiple epitopes on the same target or any other agent capable of more than one binding specificity whether in existence now or yet to be developed. The specificity of a multispecific targeting agent with regard to a cell may be determined by the difference in the number of targets expressed by the cell the multispecific targeting agent is designed to identify and the number of targets expressed by other cells. In the following nonlimiting example: one multispecific targeting agent capable of binding with three or more different targets in a tumor cell, but only a single target in a normal cell in the same tissue will have a higher specificity than a multispecific targeting agent that is capable of binding with three or more targets in a tumor cell and two or more different targets in a normal cell in the same tissue. A multispecific targeting agent should be capable of specifically binding at least two more targets expressed on the cell type it is designed to target than the number expressed on other similar tissue. While this two-or-more target excess is optimal, this aspect of the invention also encompasses an excess of one target.












TABLE 1





Target



Product
Annealing T


Sequence
Accession No.
Primer
Sequence (5′-3′)
Length (bp)
(° C.)




















IL1RAP
NM_002182
forward
gct gtg cat ctt tga ccg a
86
53





(SEQ ID NO: 51)


mRNA/cDNA

reverse
gag gcg tct gct ttt ctg aa





(SEQ ID NO: 52)


PCDHB10
NM_018930
forward
cag ggt ttc cta ctg ctg ttc
121
53





(SEQ ID NO: 53)


mRNA/cDNA

reverse
aca gga ctt gcc ttt gtc ttg





(SEQ ID NO: 54)


PTPRR
NM_002849
forward
agg agt tgt gga tgc act aag
127
53





(SEQ ID NO: 55)


mRNA/cDNA

reverse
ctg ctg aaa gtc tgc tct cat a





(SEQ ID NO: 57)


SLC2A13
NM_052885
forward
tgg gag tct ggc ttg ttg ag
82
53





(SEQ ID NO: 56)


mRNA/cDNA

reverse
ata atg agt gct acg gtg gta cc





(SEQ ID NO: 58)


















TABLE 2







Tumor Coverage by Cluster Analysis


Combination
Target Symbols
Grouping (See FIG. 3)



















1
TM4SF4
PCDHB10
FCGR1A
Group II: TPan21, TPan22, TPan24,






and TPan 25


2
IL1RAP
PCDHB10
SLC01B3
Group II: TPan21, TPan22, TPan24,






and TPan25


3
PTPRR
IL1RAP
PCDHB10
Group II: TPan22 and TPan25.






Group III: TPan26.


4
IL1RAP
PCDHB10
SLC2A13
Group II: TPan22 and TPan25.






Group III: TPan26


5
TM4SF4
PCDHB10
SLC2A13
Group II: TPan22 and TPan25.






Group III: TPan26


6
PCDHB10
FCGR1A
SLC01B3
Group II: TPan21, TPan22, TPan24






and TPan25


7
CLEC4A
PCDHB10
SLC01B3
Group II: TPan21, TPan22, TPan24






and TPan25


















TABLE 3







Tumor Coverage by Cluster Analysis Group


Combination
Target Symbols
See FIG. 3




















1
TM4SF4
FCGR1A
ASGR1
IL1RAP
Group II: TPan19, TPan21, TPan22, TPan24,







TPan25 and TPan27.


2
TM4SF4
PCDHB10
PCDHB9
IL1RAP
Group II: TPan21, TPan22, TPan24 and







TPan25







Group III: TPan26.


3
TNFSF4
TM4SF4
MGC34923
TGFBR1
Group II: TPan15, TPan19, TPan22, TPan25







and TPan27


4
PCDHB8
HLA-DQA1
PCDHB10
SLC01B3
Group II: TPan18, TPan21, TPan22, TPan24







and TPan25


5
PTPRR
PTPRC
SLC01B3
ASGR1
Group I: TPan10.







Group II: TPan20, TPan22, TPan23, TPan25







and TPan28


6
PTPRR
MS4A4A
SLC01B3
ASGR1
Group I: TPan10.







Group II: TPan20, TPan22, TPan23, TPan25







and TPan28


7
PTPRR
CEACAM6
MS4A4A
SLC01B3
Group I: TPan10.







Group II: TPan20, TPan22, TPan23, TPan25







and TPan28




















TABLE 4









Sample
Score
% of cases














Target
classification
0
1+
2+
3+
N/E
with ≧2+

















PTPRR
Normal
2
2
0
0
0
0



Tumor
0
12
28
8
4
75


PCDHB10
Normal
3
1
0
0
0
0



Tumor
1
21
22
4
4
37


IL1RAP
Normal
4
0
0
0
0
0



Tumor
6
19
18
5
4
48


SLC2A13
Normal
2
0
0
0
2
0



Tumor
7
18
18
4
5
47



















TABLE 5









Tissue













Target
PTPRR
IL1RAP
PCDHB10







Gastric Mucosa
3+
1+
1+



Small Intestine
0
2+
1+



Epididymis
1+
1+
1+



Seminiferous tubules
1+
0
2+



Gallbladder
1+
1+
0



Salivary gland
1+
0
1+



Hair follicle
0
1+
1+



Fallopian tube
2+
2+
1+



Adrenal gland
2+
0
3+



Bronchial cartilage
1+
0
1+



Uterus, smooth
1+
0
1+



muscle



Ovary, corpus luteum
1+
1+
1+



Placenta
1+
1+
1+



Appendix
0
1+
1+



Bronchial epithelium
1+
0
1+



Kidney
2+
0
2+



Bladder epithelium
1+
2+
1+




















TABLE 6









Target













Tissue
IL1RAP
PCDHB10
SLC2A13







Gastric mucosa
1+
1+
1+



Epididymis
1+
1+
0



Small Intestine
2+
1+
0



Hair follicles
1+
1+
0



Fallopian Tube
2+
1+
0



Adrenal gland
0
3+
1+



Ovary, corpus luteum
1+
1+
0



Placenta
1+
1+
0



Appendix
1+
1+
1+



Kidney
0
2+
1+



Bladder epithelium
2+
1+
1+



















TABLE 7









Target
















IL1RAP

PCDHB10

PTPRR

SLC2A13



Cell
mRNA
IL1RAP
mRNA
PCDHB10
mRNA
PTPRR
mRNA
SLC2A13


Line
(sem)#
Protein†
(sem)#
Protein†
(sem)#
Protein†
(sem)#
Protein†





AsPC-1
 1.9 (0.1)
+++
13 (3) 
+++
57 (10)
+++
90 (10)
+++


Capan-1
12 (2)
+++
5.5 (0.8)
+++
46 (8) 
+++
1.5 (0.8)
+++


HPAFII
0.63 (0.1)
+++
2.0 (0.3)
++
26 (5) 
+++
5.9 (4)  
+++


PSN-1
0.70 (0.1)
+++
0.044 (0.004)
++
 0.1 (0.09)
++
 11 (0.6)
++


SU86.86
0.62 (0.1)
+
0.009 (0.005)
++
2.3 (0.1)
++
0.39 (0.1) 
++





#Normalized to β-actin (ACTB) expression [(target 2−CT/ACTB 2−CT) * 1000]. Data are the mean of 3 samples and error values are the standard error of the mean (sem).


†Relative staining intensity as compared to no 1° Ab control: +++ = high, ++ = moderate, + = low. Controls had no staining.
















TABLE 8







Target
Designation









PCDHB10
SEQ ID NO 01



PCDHB10 protein
SEQ ID NO 02



IL1RAP
SEQ ID NO 03



IL1RAP protein
SEQ ID NO 04



SLC01B3
SEQ ID NO 05



SLC01B3 protein
SEQ ID NO 06



PTPRR isoform 1
SEQ ID NO 07



PTPRR isoform 1 protein
SEQ ID NO 08



PTPRR isoform 2
SEQ ID NO 09



PTPRR isoform 2 protein
SEQ ID NO 10



SLC2A13
SEQ ID NO 11



SLC2A13 protein
SEQ ID NO 12



FCGR1A
SEQ ID NO 13



FCGR1A protein
SEQ ID NO 14



CLEC4A isoform 1
SEQ ID NO 15



CLEC4A isoform 1 protein
SEQ ID NO 16



CLEC4A isoform 2
SEQ ID NO 17



CLEC4A isoform 2 protein
SEQ ID NO 18



CLEC4A isoform 3
SEQ ID NO 19



CLEC4A isoform 3 protein
SEQ ID NO 20



CLEC4A isoform 4
SEQ ID NO 21



CLEC4A isoform 4 protein
SEQ ID NO 22



TM4SF4
SEQ ID NO 23



TM4SF4 protein
SEQ ID NO 24



ASGR1
SEQ ID NO 25



ASGR1 protein
SEQ ID NO 26



PTPRC isoform 1
SEQ ID NO 27



PTPRC isoform 1 protein
SEQ ID NO 28



PTPRC isoform 2
SEQ ID NO 29



PTPRC isoform 2 protein
SEQ ID NO 30



PTPRC isoform 3
SEQ ID NO 31



PTPRC isoform 3 protein
SEQ ID NO 32



PTPRC isoform 4
SEQ ID NO 33



PTPRC isoform 4 protein
SEQ ID NO 34



MS4A4A
SEQ ID NO 35



MS4A4A protein
SEQ ID NO 36



TNFSF4
SEQ ID NO 37



TNFSF4 protein
SEQ ID NO 38



MGC34293
SEQ ID NO 39



MGC34293 protein
SEQ ID NO 40



TGFBR1
SEQ ID NO 41



TGFBR1 protein
SEQ ID NO 42



HLADQA1
SEQ ID NO 43



HLADQA1 protein
SEQ ID NO 44



CEACAM6
SEQ ID NO 45



CEACAM6 protein
SEQ ID NO 46



PCDHB8
SEQ ID NO 47



PCDHB8 protein
SEQ ID NO 48



PCDHB9
SEQ ID NO 49



PCDHB9 protein
SEQ ID NO 50

## Claims

1. A method of detecting a pancreatic tumor group comprising:
obtaining a sample comprising a cell from a human subject;
extracting nucleic acid from the sample;
assessing the expression of a first RNA molecule comprising SEQ ID NO 01;
assessing the expression of a second RNA molecule comprising SEQ ID NO 03;
assessing the expression of a third RNA molecule comprising a sequence selected from a set consisting of SEQ ID NO 05, and SEQ ID NO 11; and
comparing the expression of the first RNA molecule, the second RNA molecule, and the third RNA molecule to a normal pancreatic cell.

2. The method of claim 1 wherein assessing the expression comprises microarray analysis.

3. The method of claim 1 wherein assessing the expression comprises reverse transcriptase polymerase chain reaction.

4. The method of claim 1 wherein assessing the expression comprises quantitative real-time reverse transcriptase polymerase chain reaction.

5. The method of claim 1 wherein the nucleic acid comprises mRNA.